Avidity Biosciences Inc. (RNA) News

Avidity Biosciences Inc. (RNA): $39.96

1.60 (+4.17%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

Add RNA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#328 of 356

in industry

Filter RNA News Items

RNA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RNA News Highlights

  • RNA's 30 day story count now stands at 2.
  • Over the past 8 days, the trend for RNA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest RNA News From Around the Web

Below are the latest news stories about AVIDITY BIOSCIENCES INC that investors may wish to consider to help them evaluate RNA as an investment opportunity.

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on December 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 7,100 shares of its common stock and 3,550 restricted stock units ("RSUs") to two (2) new non-executive employees under the Avidity Bioscie

Yahoo | December 21, 2023

Avidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers from Phase 1/2 EXPLORE44™ Trial for Duchenne Muscular Dystrophy

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced positive AOC 1044 data in healthy volunteers from the Phase 1/2 EXPLORE44™ clinical trial for the treatment of Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44). AOC 1044 delivered unprecedented concentrations of phosphorodiamidate morpholino oligomers (PMO) in skeletal muscle with

Yahoo | December 13, 2023

The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie

Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie are included in this Analyst Blog.

Yahoo | December 1, 2023

Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More

Regulatory and pipeline updates from Avidity Biosciences, Inc. (RNA) and BioVie (BIVI) are in the spotlight this week.

Yahoo | November 30, 2023

Company News for Nov 29, 2023

Companies in The News Are: ESLT,RNA,ZS,SDRL

Yahoo | November 29, 2023

Avidity (RNA) Expands Collaboration With BMY, Shares Rise

Avidity (RNA) gains on the expansion of its existing partnership with BMY to discover multiple cardiovascular targets.

Yahoo | November 29, 2023

Why Is Avidity Biosciences (RNA) Stock Up 15% Today?

RNA stock is jumping over 15% in early trading after Avidity announced its expanded alliance with Bristol-Myers Squibb.

Larry Ramer on InvestorPlace | November 28, 2023

FCEL Stock Alert: FuelCell Energy Announces AI Deal With IBM

FuelCell Energy stock is climbing higher on Tuesday as investors in FCEL celebrate the company signing a deal with IBM!

William White on InvestorPlace | November 28, 2023

Lion Electric Layoffs 2023: What to Know About the Latest LEV Job Cuts

Lion Electric layoffs are coming for 150 of the electric bus company's employees as it seeks to reduce its headcount by 10%.

William White on InvestorPlace | November 28, 2023

Novocure Layoffs 2023: What to Know About the Latest NVCR Job Cuts

Novocure layoffs are coming for 13% of the company's workers as it seeks to reduce its headcount by 200 people to reduce costs.

William White on InvestorPlace | November 28, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!